Active and completed trials
- NCT01682044: Pegfilgrastim and Rituximab in Treating Patients with Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
- NCT03682796: Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
- NCT01959698: Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
- NCT01527149 Ofatumumab in Combination with Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
- NCT04803201: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- NCT04541017: Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
- NCT05079282: Study of ONO-4685 in Patients with Relapsed or Refractory T Cell Lymphoma
- NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients with Primary Central Nervous System Lymphoma (PROSPECT Study)
- NCT05605899: Study to Compare Axicabtagene Ciloleucel with Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)
- NCT05972720: A Phase 2 Study of CRG-022 in Patients with Relapsed/Refractory Large B-cell Lymphoma
- NCT04982471: Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
- NCT06047080: An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
- NCT05508867: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
- NCT03179930: Combination Therapy with Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
- NCT04799275: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma
- NCT02952508: Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)
- NCT05057494: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAJIC)
- NCT03435796: Long-Term Follow-up Protocol for Participants Treated with Gene-Modified T Cells
- NCT05578976: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined with Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)
- NCT05409066: Study of Subcutaneous Epcoritamab in Combination with Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)
- NCT05544019: Study of SGR-1505 in Mature B-Cell Neoplasms
Connect with the Hernandez-Ilizaliturri Lab
Department of Immunology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263